BIOMARIN PHARMACEUTICAL INC Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock of 30 shares for the 1-month period ending 2009-03-26, per its 10-K filed 2012-02-22.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock · last filed 2012-02-22
- 2009-03-26: Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 1 month 30.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 1 month |
|---|---|
| 2009-03-26 | 30.00 shares 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |